Clinical Trials Directory

Trials / Completed

CompletedNCT07078071

Clinical Trial for Evaluating the Effectiveness and Safety of the Pulse Wave-based Atrial Fibrillation and Premature Beat Alert Software

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
199 (actual)
Sponsor
Huawei Device Co., Ltd · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This study aims to validate the efficacy and safety of the Pulse Wave-based Atrial Fibrillation and Premature Beat Alert Software (Huawei Device Co., Ltd.). This software can provide alerts, store and display PPG data transmitted from smartwatches or fitness trackers. The software is limited to alerting of atrial fibrillation and premature beat, and the results are only for clinical reference.

Conditions

Interventions

TypeNameDescription
DEVICEECGEach participant undergoes testing with both the investigation device and the control device simultaneously. The results of the investigation device, which are obtained through pulse wave data analysis at the wrist, are compared to the investigator's interpretation of the ECG.

Timeline

Start date
2022-10-18
Primary completion
2023-03-01
Completion
2023-03-01
First posted
2025-07-22
Last updated
2025-07-22

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07078071. Inclusion in this directory is not an endorsement.